SynthesisInternational journal of molecular sciences2020
The Relationship between DNA Methylation and Antidepressant Medications: A Systematic Review.
Synthesis in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it, 85 citations in OpenAlex.
- Brain-Derived Neurotrophic Factor (BDNF) as a Predictor of Treatment Response in Major Depressive Disorder (MDD): A Systematic Review.International journal of molecular sciences · 2023Pooled it
- Effects of 6-months of SSRI use on DNA-methylation and gene expression in blood.Brain, behavior, and immunity · 2026Trial
- Epigenome-wide association study of psilocybin-induced methylome changes in alcohol use disorder.Translational psychiatry · 2026Trial
- Epigenetic signatures in antidepressant treatment response: a methylome-wide association study in the EMC trial.Translational psychiatry · 2022Trial
- Mapping DNA Methylation Signatures to Identify Epigenetic Variation Across Subcortical Regions of the Human Posttraumatic Stress Disorder Brain.Biological psychiatry · 2026Article
- MTHFR and MTRR Polymorphisms Predict Sex-Dependent Psychotic Symptom Improvements, Not Metabolic Changes.International journal of molecular sciences · 2026Article
- DNA hypomethylation of theFrontiers in neurology · 2026Article
- Review
- MicroRNAs: A Novel Approach for Monitoring Treatment Response in Major Depressive Disorder?Non-coding RNA · 2025Review
- Insights from a methylome-wide association study of antidepressant exposure.Nature communications · 2025Article
- Epigenome-Wide DNA Methylation in Unipolar Depression: Predictive Biomarker of Antidepressant Treatment Response?The international journal of neuropsychopharmacology · 2024Article
- Models for depression recognition and efficacy assessment based on clinical and sequencing data.Heliyon · 2024Article
- Optimizing and Predicting Antidepressant Efficacy in Patients with Major Depressive Disorder Using Multi-Omics Analysis and the Opade AI Prediction Tools.Brain sciences · 2024Article
- Article
- Biomarkers of Depression among Adolescent Girls: BDNF and Epigenetics.International journal of molecular sciences · 2024Article
- DNA methylation may partly explain psychotropic drug-induced metabolic side effects: results from a prospective 1-month observational study.Clinical epigenetics · 2024Observational
- DNA Methylation Patterns in Relation to Acute Severity and Duration of Anxiety and Depression.Current issues in molecular biology · 2023Article
- Pilot study of genome-wide DNA methylation and gene expression for treatment response to escitalopram in panic disorder.World journal of psychiatry · 2023Article
- Antidepressant and Anxiolytic Effects of L-Methionine in the WAG/Rij Rat Model of Depression Comorbid with Absence Epilepsy.International journal of molecular sciences · 2023Article
- YBX1-Mediated DNA Methylation-Dependent SHANK3 Expression in PBMCs and Developing Cortical Interneurons in Schizophrenia.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Major depressive disorder (MDD) is the leading cause of disability worldwide and is associated with high rates of suicide and medical comorbidities. Current antidepressant medications are suboptimal, as most MDD patients fail to achieve complete remission from symptoms. At present, clinicians are unable to predict which antidepressant is most effective for a particular patient, exposing patients to multiple medication trials and side effects. Since MDD's etiology includes interactions between genes and environment, the epigenome is of interest for predictive utility and treatment monitoring. Epigenetic mechanisms of antidepressant medications are incompletely understood. Differences in epigenetic profiles may impact treatment response. A systematic literature search yielded 24 studies reporting the interaction between antidepressants and eight genes (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.